An open-label phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in chronic lymphocytic leukemia (original) (raw)
Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
Vi Lam
Haematologica, 2021
View PDFchevron_right
Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Nina Chevalier
Cancer Research, 2009
View PDFchevron_right
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
Vicky Jones
British journal of haematology, 2018
View PDFchevron_right
The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia
anjali pandey
Journal of Pharmacology and Experimental Therapeutics, 2013
View PDFchevron_right
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Ephraim Hochberg
Clinical Cancer Research, 2011
View PDFchevron_right
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
Julio cesar Feria chavez
Core Evidence, 2013
View PDFchevron_right
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
Joanna Rhodes
Drug Design, Development and Therapy
View PDFchevron_right
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia
Stephen Schuster
Haematologica, 2020
View PDFchevron_right
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study
Stephen Schuster
British journal of haematology, 2017
View PDFchevron_right
Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Dharamvir Jain
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2014
View PDFchevron_right
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Andrzej Mital
Journal of Clinical Oncology
View PDFchevron_right
Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
kristin kistler
Drugs - real world outcomes, 2022
View PDFchevron_right
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression
Paula Cramer
Future Oncology, 2015
View PDFchevron_right
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Wayne Rothbaum
Journal of Clinical Oncology
View PDFchevron_right
Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
Cancer Drug Resistance, John Seymour
Cancer Drug Resistance, 2020
View PDFchevron_right
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience
Stephen Schuster
Blood, 2016
View PDFchevron_right
The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia
Wyndham Wilson
Blood, 2015
View PDFchevron_right
Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
maliha khan
OncoTargets and Therapy, 2017
View PDFchevron_right
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
Maria Tibiletti
Hematological Oncology, 2011
View PDFchevron_right
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
anjali pandey
Leukemia, 2012
View PDFchevron_right
The dual Syk/JAK inhibitor cerdulatinib antagonises B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia
anjali pandey
Clinical cancer research : an official journal of the American Association for Cancer Research, 2016
View PDFchevron_right
Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia
Darren Newton
British Journal of Haematology
View PDFchevron_right
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
S. Herman, Erin Hertlein
Blood, 2011
View PDFchevron_right
Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia
Wael Harb
Haematologica, 2016
View PDFchevron_right
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia
Joseph Beyene
View PDFchevron_right
Targeting the SYK–BTK axis for the treatment of immunological and hematological disorders
Matthew Lucas
Pharmacology & Therapeutics, 2013
View PDFchevron_right
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Jennifer Woyach
The New England journal of medicine, 2015
View PDFchevron_right
Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
Aydan AKDENİZ
Turkish Journal of Hematology, 2021
View PDFchevron_right
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Jennifer Woyach
JAMA Oncology, 2015
View PDFchevron_right
Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review
muhammad abuzar
Journal of Hematology, 2019
View PDFchevron_right